Visual field defect during therapy with valproic-acid

European Journal of Neurology

Volumn 14, Issue 8, 2007, Pages 929-932

  Tilz, C ^a   Wang Tilz, Y ^b   Junemann A ^b   Stefan, H ^b   Michelson, G ^b  

^a KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antiepileptic drugs; Valproic acid; Visual field

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; AUTOMATION; BLOOD ANALYSIS; CASE REPORT; DRUG MECHANISM; DRUG SUBSTITUTION; ELECTROENCEPHALOGRAM; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; HUMAN; METABOLIC DISORDER; PERIMETRY; PRIORITY JOURNAL; SIDE EFFECT; URINALYSIS; VISUAL FIELD DEFECT; WEIGHT GAIN;

ADULT; EPILEPSY; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RETINA; RETINAL DEGENERATION; TIME; TRANSAMINASES; UREA; VALPROIC ACID; VISION DISORDERS; VISUAL FIELDS;

EID: 34547099805     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01524.x     Document Type: Article

References (16)

1. Hilton E, Hosking S, Betts T. The effect of antiepileptic drugs in visual performance. Seizure 2004 13 : 113 128.
2. Harding G, Wild J, Robertson K, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin. Neurology 2000 55 : 347 352.
3. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. Gamma-Vinyl GABA (4-Amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. Journal of Neurochemistry 1977 29 : 797 802.
4. Lorenz R, Kuck H. Visuelle Störungen durch diphenylhydantoin: Klinische und elektroophtalmologische Befunde. Klinisches Monatsblatter Augenheilkunde 1988 192 : 244 247.
5. Ozkul Y, Gurler B, Uckardes A, Bozlar S. Visual functions in epilepsy patients on valproate monotherapy. Journal of Clinical Neuroscience 2002 9 : 247 250.
6. Thrakral A, Shenoy R, Deleu D. Acute visual dysfunction following phenytoin-induced toxicity. Acta Neurologica Belgica 2003 103 : 218 220.
7. Perucca E. Antiepileptic drugs. In : The side effect of drugs, Elsevier Science: Aronson Annual 1998 21 : 66 84.
8. Harding G, Robertson K, Edson A, Barnes P, Wild J. Visual electrophysical effect of a GABA transaminase blocker. Documenta Ophthalmologica 1998-99 97 : 179 188.
9. Pourcho RG. Uptake of [H3]glycine and [H3]GABA by amacrine cells in the cat retina. Brain Research 1980 198 : 33 46.
10. Best JL, Acheson JF. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005 19 : 41 44.
11. Krauss G, Johnson M, Sheth S, Miller N. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. Journal of Neurology, Neurosurgery, and Psychiatry 2003 74 : 339 343.
12. Herranz JL. Gabapentin: its mechanisms of action in the year 2003. Revista de neurologia 2003 36 : 1159 1165.
13. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Current Opinion in Pharmacology 2006 6 : 108 113.
14. Ben-Menachem E, French J. Vigabatrin. In : Engel J, Pedley TA, eds. Epilepsy: A comprehensive textbook. Philadephia : Lippincott-Rave Publishers, 1997 : 1609 1618.
15. Schmitz B, Jokiel B, Schmidt T, Tiel-Wilck K, Rüther K. Visual Field Loss under treatment with Vigabatrin, Carbamazepine and valproate: a prospective study. Epilepsia 1999 40 (Suppl. 2 257.
16. Jung P, Doussard-Lefaucheux S. Alteration du champ visuel chez une patiente traitée par valproate de sodium puis carbamazepine. Revue Neurologique 2002 158 : 477 479.